EP4709727A1 - Procédés et compositions de dégradation ciblée de protéines - Google Patents

Procédés et compositions de dégradation ciblée de protéines

Info

Publication number
EP4709727A1
EP4709727A1 EP24735385.7A EP24735385A EP4709727A1 EP 4709727 A1 EP4709727 A1 EP 4709727A1 EP 24735385 A EP24735385 A EP 24735385A EP 4709727 A1 EP4709727 A1 EP 4709727A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
compound
het
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24735385.7A
Other languages
German (de)
English (en)
Inventor
Chenghao YING
Guoqiang Wang
Zhiyong Wang
Zimo Yang
Jinhua LI
Yaya WANG
Yan Dai
Weiwen Ying
Kevin P. Foley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranok Therapeutics Hangzhou Co Ltd
Original Assignee
Ranok Therapeutics Hangzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranok Therapeutics Hangzhou Co Ltd filed Critical Ranok Therapeutics Hangzhou Co Ltd
Publication of EP4709727A1 publication Critical patent/EP4709727A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des PROTAC constituées d'une fraction de ciblage conçue pour se lier à KRAS (G12D/C/V) lié à une fraction de direction de dégradation conçue pour se lier à une ubiquitine-ligase E3. L'invention concerne également des compositions pharmaceutiques comprenant les PROTAC décrites et leur utilisation dans le traitement du cancer et d'états associés.
EP24735385.7A 2023-05-09 2024-05-09 Procédés et compositions de dégradation ciblée de protéines Pending EP4709727A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023093091 2023-05-09
PCT/US2024/028674 WO2024233838A1 (fr) 2023-05-09 2024-05-09 Procédés et compositions de dégradation ciblée de protéines

Publications (1)

Publication Number Publication Date
EP4709727A1 true EP4709727A1 (fr) 2026-03-18

Family

ID=91621253

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24735385.7A Pending EP4709727A1 (fr) 2023-05-09 2024-05-09 Procédés et compositions de dégradation ciblée de protéines

Country Status (3)

Country Link
EP (1) EP4709727A1 (fr)
CN (1) CN121487938A (fr)
WO (1) WO2024233838A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
CN121941690A (zh) 2023-10-03 2026-04-28 Paq医疗公司 Kras蛋白水解靶向嵌合体
CN120004917A (zh) * 2023-11-15 2025-05-16 上海医药集团股份有限公司 一种靶向蛋白调节剂的化合物及其应用
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117222650A (zh) * 2021-04-30 2023-12-12 劲方医药科技(上海)有限公司 吡啶或嘧啶并环类化合物，其制法与医药上的用途
WO2022266206A1 (fr) * 2021-06-16 2022-12-22 Erasca, Inc. Conjugués d'inhibiteurs de kras
WO2023061463A1 (fr) * 2021-10-15 2023-04-20 广东东阳光药业有限公司 Nouveau composé de pyrimidopyridine, composition pharmaceutique de celui-ci et utilisation associée

Also Published As

Publication number Publication date
CN121487938A (zh) 2026-02-06
WO2024233838A1 (fr) 2024-11-14

Similar Documents

Publication Publication Date Title
WO2024233838A1 (fr) Procédés et compositions de dégradation ciblée de protéines
WO2023081476A1 (fr) Procédés et compositions pour la dégradation ciblée de protéines
US20240116950A1 (en) Inhibitors of kras(g12d)
WO2024044334A2 (fr) Procédés et compositions de modulation de kras(g12d)
WO2023220421A1 (fr) Inhibiteurs de kras (g12d)
WO2024123913A1 (fr) Inhibiteurs de kras (g12v)
CN113939516B (zh) 用于靶向蛋白降解的方法和组合物
WO2024227091A1 (fr) Inhibiteurs diazabicyclooctanes de kras g12d et utilisations
KR20230019101A (ko) 벤조티아졸릴 비아릴 화합물, 제조 방법 및 용도
EP4626895A1 (fr) Dérivés de 4-(3,8-diazabicyclo [3.2.1]octan-3-yl)-pyrido[4,3-d]pyrimidine utilisés en tant qu'inhibiteurs de l'oncoprotéine à mutation kras (g12d) pour le traitement du cancer
WO2025019666A1 (fr) Procédés et compositions de modulation de shp2
AU2021362975A1 (en) Methods and compositions for targeted protein degradation
EP4228700A1 (fr) Méthodes et compositions pour la dégradation de protéines ciblées
CN109761986B (zh) 三并环类衍生物抑制剂、其制备方法和应用
EP4687908A1 (fr) Procédés et compositions pour la dégradation ciblée de protéines
EP4229061A1 (fr) Méthodes et compositions pour la dégradation ciblée de protéines
RU2820673C2 (ru) Способы и композиции для направленной деградации белка
WO2025199665A1 (fr) Procédés et compositions pour la dégradation ciblée de protéines

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR